Xeris Pharmaceuticals Inc (XERS) Receives a Buy from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals Inc (XERS), with a price target of $27. The company’s shares closed yesterday at $9.84, close to its 52-week low of $9.21.

Yang wrote:

“We believe this financing is positive for a number of reasons: 1) Provides financing through 2022, by which time we believe Xeris can be cash break-even; 2) Allows management to focus on the Gvoke HypoPen launch, 3) Avoids the potential pitfall of “short the launch” phenomenon, 4) Creates opportunities for higher long-term growth by optimal upfront investment in the company. We maintain our Buy rating and $27 PT assuming Gvoke Hypopen NDA approval in ~50% market share 6-7 years post launch.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 15.8% and a 47.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xeris Pharmaceuticals Inc with a $27 average price target.

See today’s analyst top recommended stocks >>

Based on Xeris Pharmaceuticals Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $14.77 million. In comparison, last year the company had a GAAP net loss of $7.53 million.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, Inc.is a pharmaceutical company. It offers XeriSol™ and XeriJect™ formulation technologies. The firm focuses on the development of patient-friendly injectable drugs to address unmet medical needs. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.